A significant number of all invasive breast cancers are hormone sensitive and may be
candidates for treatment with hormonal therapy.
This project will assess the ability and usefulness of imaging hormone-receptor status in
breast cancer with positron emission tomography (PET) and 6α-[18F]fluoro-17β-estradiol (FES),
an estrogen analogue in patients who are scheduled to be treated with hormonal therapy given
in combination with a selective allosteric inhibitor of AKT protein kinase (MK2206) .